"...Paul Hopper's ability to pick up strong oncology assets on excellent valuations."The Hopper oncology deal was announced on St Patricks Day.VHL shares have been falling ever since - today sunk to $0.07. Why?Because the market takes issue with your Hopper deal sentiment, maybe.Directors have yet to explain why Hopper's oncology drug was discarded by previous licensee after Phase 1 trial.Hopper publicly silent. Millen also.As for Edison Research, I note the firm expects any TG-4010 royalties flowing via Transgene will be deferred two years 'til 2018. Still, if BMS or Merck emerge as TG-4010 backers, VHL may rise from the floor.
(20min delay)